Polycystic Ovary Syndrome (PCOS) has been officially reclassified as Polyendocrine Metabolic Ovarian Syndrome (PMOS) as of May 12, 2026. This change, reported in The Lancet, reflects a broader understanding of the condition, recognizing it as a systemic hormonal and metabolic disorder rather than solely focusing on ovarian cysts. The rebranding aims to enhance the long-term care and treatment options available for the approximately 170 million women affected by this condition globally.
Related Articles
Don't miss out on breaking stories and in-depth articles.